Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback